Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen confirms Parkinson’s drug risks
As part of that decision, Amgen has also concluded that it will not provide GDNF (glial-cell-lined-derived neurotrophic factor) to the 48 patients who participated in clinical trials that
As part of that decision, Amgen has also concluded that it will not provide GDNF (glial-cell-lined-derived neurotrophic factor) to the 48 patients who participated in clinical trials that
The blinded, placebo-controlled 60-patient study, named “La Plata”, showed a statistically-significant improvement in an important measurement of cardiac function, the left ventricle ejection fraction (LVEF). Following 28 days
Pursuant to the settlement, Alpharma has waived its FDA-awarded 180-day marketing exclusivity, enabling Ivax to begin selling gabapentin capsules from March 23, 2005 and gabapentin tablets from April
In the study, Zomig nasal spray (zolmitriptan) provided significant migraine headache response and pain-free rates as early as 15 minutes post-dose in migraine sufferers, with significantly higher sustained
Parkinson’s disease is the focus of two of Cambria’s phase I small business innovation research (SBIR) grants, one from the National Institute of Neurological Disorders and Stroke and
Under the agreement with the National Research Council of Canada (NRC), BioVeris has acquired worldwide, exclusive rights to commercialize products for possible use in the prevention, diagnosis and
The trial, which commenced on December 2, is currently being conducted at 32 centers across Canada and will evaluate ISA247, the company’s lead immunosuppressive compound, in patients with
The purchasing holding company is controlled by the Altor 2003 Fund and pre-existing shareholder Idosan. Novo Nordisk has been a minority shareholder, owning around 29% of the capital,
The vaccine is based on proprietary Antigen Express technology that employs modified peptide antigens to stimulate immunity. Antigen Express proprietary technologies dramatically enhance the immunogenicity of small fragments
The special protocol assessment (SPA) specifies the trial objectives and design, clinical endpoints, and planned analyses that would be needed to apply for product approval. The phase III,